Archivi News - Kedrion Biopharma

Choose your country

Find in Kedrion

Fostering dialogue between industry and European institutions

May 29, 2026 | CORPORATE

€150 million investment to triple Kedrion’s production capacity: Italy’s “Plasma Valley” to treat rare diseases

May 11, 2026 | CORPORATE

FAB 13: New results confirm the strength of the Italian pharmaceutical model. Kedrion’s contribution in rare and ultra‑rare diseases

Jan 20, 2026 | CORPORATE

Institutional visit to our Bolognana plant: innovation, local community, and plasma supply chain at the heart of the discussion

Dec 22, 2025 |

Fondazione Carlo Erba and Kedrion: Research Awards presented in Milan. Young talents and innovation for health

Dec 12, 2025 | EVENTS

EMA grants Orphan Drug Designation to our plasma-derived treatment for Aceruloplasminemia, a rare genetic disorder of iron metabolism

Nov 27, 2025 |

SISET Congress: a session on the role of FVIII beyond coagulation

Nov 24, 2025 | EVENTS

Kedrion receives US approval for new 10% intravenous Immunoglobulin, the result of Italian investment and know-How

Oct 08, 2025 | CORPORATE

A new standard in Social Responsibility: PAS 24000 achieved

Aug 01, 2025 | CORPORATE

Gender Equality: a commitment that starts with people

Jul 16, 2025 | CORPORATE

For more information please contact: [email protected]

You are now leaving www.kedrion.it. Medical information including licensed uses may be different outside of Italy.

No